Most Exhaustive Report

AKT Inhibitors - Pipeline Insights 2018

Most Exhaustive Report

AKT Inhibitors - Pipeline Insights 2018

SKU : APA17802 Published on : February 2018 Pages : 70

${{licencetype}}

Get 10% Free Customization
On This Report.
Customize this report Enquire before buying

Get actionable insights on how COVID-19 is impacting your business sector.

Enquire now

The serine/threonine kinase ‘AKT’, commonly known as protein kinase B or PKB, plays a vital role in regulating diverse cellular functions. AKT has three isoforms (AKT1, AKT2 and AKT3) which play a vital role in diverse cellular functions including cell size/growth, proliferation, survival, glucose metabolism, genome stability, transcription and protein synthesis, and neovascularization. A plethora of studies supports have proven that the AKT signaling cascade is frequently impaired in many types of cancers, including, breast, lung, gastric, ovary and pancreas. It is also proven to be associated with tumor aggressiveness. Thus AKT is considered as one a potent target candidate for cancer therapy. AKT inhibitors are targeted drug molecules that hold the potential to inhibit the activated form of AKT that leads to normal functioning of AKT kinases.

Research and development activity for AKT inhibitors is quite robust. Clinical experiments on investigational AKT molecules are focused on cancers including breast cancer, gastric cancer, prostate cancer, multiple myeloma. The AKT inhibitors pipeline has more than 20 molecules across various stages of clinical development which are likely to gain regulatory approval in foreseeable future. Few of the key pipeline AKT inhibitors include AT13148, SR13688, LY2780301, BAY 1125976, AZD5363, GSK690693, and A 443654. In pipeline analysis, these molecules are analyzed on the basis of route of administration (ROA) and type of molecule. The pipeline is also assessed based on monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage. Few of the key companies which are involved in the development of Akt inhibitors include Otsuka, Eli Lilly, Bayer, GSK, Merck, Novartis, Amgen, and AbbVie.

Reasons to Buy

  • To gain erudite insights about the AKT inhibitor pipeline landscape
  • To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine
  • To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market
  • To identify competitors and design strategic initiatives for drug development activities
  • To understand the market and choose right partners for strategic collaborations
  • To obtain informed updates on drug termination/drug discontinuation

FILL IN YOUR DETAILS BELOW TO GET FREE SAMPLE OF THIS REPORT

Client Speak

Erik Young

CEO, Co-founder
Audink Inc., DBA Audios

The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow.

Benjamin Arnold

Senior Product Manager
Interstates

I recently purchased a key Arizton Industry Outlook & Forecast in order to better understand growth for specific market segments and the macro environmental factors impacting this growth. I found Ariztonā€™s coverage of the market dynamics and key takeaways to be insightful and valuable. The segmentation breakouts gave me the information I needed to guide strategic considerations.

Hallmann, Nickolai

Manager Market Analyst Power
Generation & Energy
Rolls-Royce Power Systems AG

The provided information by Arizton really met my expectations. Especially the deep information about the datacenter ecosystem was very helpful. Furthermore, I absolutely appreciate the optimal service from the key account managers of Arizton. It was always a pleasure working with them.

Support

+1-312-235-2040

Copyright 2019 - Arizton